However, there is inconsistent data concerning the prognostic impact of CDKN2A/B deletion in patients already presenting with morphological characteristics of WHO grade 4 astrocytoma [2, 4, 10–12]. The gene discussed is CDKN2A; the disease is astrocytoma (excluding glioblastoma).